Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate how the use of Tranexamic acid and Bacitracin applied to the bleeding site after the hemodialysis fistula needle is removed will affect Time to Clot and Infection Rate

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: California Institute of Renal Research
• Collaborator: Imprimis Pharmaceuticals, Inc.
• Treatments: Bacitracin; Tranexamic Acid

Criteria

Inclusion Criteria:

• Dialysis patients with fistulas (native arterio-venous)

Exclusion Criteria:

• Previous sensitivity to or adverse reaction to Tranexamic acid or Bacitracin.

• Active infection.

• Stenosis of fistula.